Assessing Cosopt Switch Patients

Completed · Phase 4

Conditions studied: Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary

In brief

To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.

Key facts

Study ID

NCT00273442

Run by

Pharmaceutical Research Network

People needed

60

Starts

2005-11-01

Expected to finish

2007-04-01

Last updated by the study team

2008-11-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension
• the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM
• visual acuity should be 20/200 or better in each eye

You may not qualify if…

• contraindications to study drugs
• anticipated change in systemic hypotensive therapy during the trial
• use of any corticosteroids by any route in the three months immediately prior to Visit 2

Where it is running

• Little Rock Eye Clinic — Little Rock, Arkansas, United States
• Omni Eye Services — Atlanta, Georgia, United States
• Midwest Eye Center — Bourbonnais, Illinois, United States
• Mark J. Weiss, MD — Tulsa, Oklahoma, United States
• Glaucoma Consultants & Center for Eye Research — Mt. Pleasant, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.